For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241022:nRSV1760Ja&default-theme=true
RNS Number : 1760J IXICO plc 22 October 2024
22 October 2024
IXICO PLC
("IXICO" or the "Company")
Correction of clerical error
IXICO plc (AIM: IXI), has become aware of a clerical error in resolutions 1
and 3 (the "Resolutions") as set out in the notice of general meeting
accompanying the circular sent to shareholders dated 9 October 2024 (the
"Circular") convening a general meeting for 25 October 2024 (the "General
Meeting"). The Resolutions seek shareholder authority to issue the New
Ordinary Shares in connection with the Fundraising. The aggregate nominal
value of shares referred to in the Resolutions should have been £447,368.42
rather than £42,500. This corrected figure is consistent with the figures
relating to the Fundraising set out elsewhere in the Circular.
In accordance with its articles of association the Company intends to propose
additional ordinary resolutions at the General Meeting to amend the
Resolutions and correct this error.
Shareholders do not need to take any further action in relation to the
business to be conducted at the Meeting.
Defined terms used in this announcement have the meanings given to them in the
Circular unless otherwise stated.
For further information please contact:
IXICO plc +44 (0) 20 3763 7499
Bram Goorden, Chief Executive Officer
Grant Nash, Chief Financial Officer
Cavendish Capital Markets Limited +44 (0) 20 7220 0500
(Nominated adviser and sole broker)
Giles Balleny / Dan Hodkinson (Corporate Finance)
Nigel Birks (Life Sciences Specialist Sales)
Harriet Ward (Corporate Broking)
Michael F Johnson / Tamar Cranford Smith (Sales)
About IXICO
IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's disease, Parkinson's disease and Alzheimer's disease. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.
IXICO has developed and deployed breakthrough data analytics, at scale,
through its remote access technology platform, to improve the return on
investment in drug development and reduce risk and uncertainty in clinical
trials for the Company's pharmaceutical clients.
More information is available on www.IXICO.com (http://www.ixico.com/) and
follow us on X (formerly Twitter) @IXICOnews
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END MSCKZMZGFZKGDZM